World First at Maria Middelares Hospital in Belgium Thanks to da Vinci SP’s Innovative Technology
29.5.2024 15:37:00 EEST | Business Wire | Press release
As part of the new Health Value Space Ghent, Maria Middelares Hospital continues to lead the way as a “smart” hospital, poised to deliver healthcare of the future to its patients. The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision. It was on May 27 that a world first took place at the hospital: a kidney autotransplantation assisted by the da Vinci SP surgical system.
The arrival of Intuitive’s new da Vinci SP system aligns perfectly with Maria Middelares' vision of developing a patient-oriented robotics platform. The SP enables more complex procedures to be performed through a single incision or natural orifice. Over 400 peer-reviewed publications demonstrate the safety, efficacy, and excellent results of this cutting-edge technology. The da Vinci SP offers incredible value on a daily basis for Maria Middelares and its patients.
- A World First
On May 27, urologist Prof. dr. Decaestecker achieved a world first. Using the da Vinci SP, he performed an intracorporeal kidney autotransplantation on an 18-year-old woman suffering from a complex ureteral lesion, with severe damage to the ureter between the kidney and the bladder. The best solution for the patient was to bridge the major defect in the ureter by moving the kidney closer to the bladder. This technique is called autotransplantation.
The transplantation was achieved intracorporeally, meaning entirely inside the body. Prof. dr. Decaestecker has perfected this technique, having performed such operations since 2017 (a European first at the time) using the da Vinci Multiport system, equipped with four robotic arms. The advantage of an in-body operation is that no large incisions are required to move the kidney in and out of the body; only a few small incisions (with the Multiport) of around 1 cm were needed to introduce the robotic instruments.
Prof. dr. Decaestecker explains: “What’s new now is the combination of in-body grafting with a single incision thanks to the SP robotic system, which has just one articulated arm. This is less intrusive for the patient’s body and should also facilitate smoother post-op recovery. Other advantages are that we can perform the procedure entirely outside the abdomen, allowing the patient to lie flat on their back in a natural position. This is important as the patient can now be operated on in a more comfortable position, therefore with fewer intestinal complications.”
- What does the future hold?
With the development of a robotics platform, Maria Middelares aims to optimize the use of robotic systems within the operating room as much as possible. The goal is to improve operating room efficiency and patient outcomes. These innovative surgical systems allow for further personalization of surgery based on patient needs.
Dr. Ameye, Director of Innovation, adds: “In our organization, we strive to seek out the best technology combined with in-depth monitoring. We map the quality of care using big data analysis based on a multitude of uniform data. This enables us to identify areas for improvement and continuously optimize our care. Providing value-based healthcare is our main motivation.”
You can download images from the operating room of this world premiere via this link.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529830425/en/
Contact information
For further information
Catherine Zenner, Head of Communications Maria Middelares
catherine.zenner@mijnziekenhuis.be or 0478 99 53 11.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
